Tarsus Pharmaceuticals, Inc.
TARS
Positions held
Your positionsTARS isn't in your positions.
Add it to see shares, cost, and P&L here.
Bull / bear case
Site-generated summary from fundamentals, news, and score — not investment advice. As of 2026-10-08.
- Tarsus Pharmaceuticals operates in the biotechnology sector, which is characterized by rapid innovation and significant growth potential, particularly in developing treatments for unmet medical needs.
- The company's revenue grew by 7% in the last quarter, reaching $174 million compared to $162 million in the prior quarter.
- Tarsus has a strong gross margin of 93%, indicating efficient production and pricing strategies.
- The biotechnology industry faces intense competition, which can impact market share and pricing power for companies like Tarsus Pharmaceuticals.
- Tarsus reported a net income loss of $18.551 million in the most recent quarter, highlighting ongoing financial challenges.
- The company's operating margin has been negative, with a recent figure of -11.4%, indicating difficulties in managing operational costs.
Fundamentals
| Market cap | $3.38B | Enterprise value | $2.81B | Trailing P/E | — | Forward P/E | -200.61 |
| PEG | — | Price / book | 9.01 | Beta | 0.45 | Dividend yield | 0.00% |
| Revenue growth | 69.4% | Earnings growth | — | Gross margin | 82.7% | Operating margin | -11.4% |
| Profit margin | -7.7% | ROE | -13.7% | ROA | -5.5% | Debt / equity | 0.26 |
| Current ratio | 3.20 | Free cash flow | $67.47M | Analyst recommendation | strong_buy | Mean target | $99.50 |
| 52w high | $91.53 | 52w low | $53.89 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $174M | $162M | $152M | $119M | $103M | — |
| Op margin | -11.4% | -3.8% | -5.3% | -12.2% | -21.6% | — |
| Net income | -$18.6M | -$7.0M | -$8.4M | -$12.6M | -$20.3M | — |
| Gross margin | 93.0% | 94.2% | 92.8% | 93.0% | 93.9% | — |
| Gross profit | $162M | $153M | $141M | $110M | $96.4M | — |
| Operating income | -$19.9M | -$6.1M | -$8.0M | -$14.5M | -$22.2M | — |
- Revenue +7% vs prior quarter ($174M vs $162M).
- Gross margin 93% (was 94.2% prior quarter).
- Operating margin compressed to -11.4%.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $451M | $183M | $17.4M | $25.8M | — |
| Op margin | -15.7% | -65.9% | -820.5% | -242.9% | — |
| Net income | -$66.4M | -$116M | -$136M | -$62.1M | — |
| Gross margin | 93.2% | 93.0% | 90.9% | 96.3% | — |
| Gross profit | $421M | $170M | $15.9M | $24.9M | — |
| Operating income | -$71.0M | -$121M | -$143M | -$62.7M | — |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-09-18 · When To Dump Stocks: These IBD 50 Components Hit Sell Signals
2026-09-17 · Tarsus Pharmaceuticals Insider Sold Shares Worth $979,744, According to a Recent SEC Filing
2026-09-09 · Tarsus Pharmaceuticals Insider Sold Shares Worth $387,940, According to a Recent SEC Filing
2026-09-09 · Tarsus Pharmaceuticals Insider Sold Shares Worth $1,220,885, According to a Recent SEC Filing
2026-09-04 · Update: Tarsus Pharmaceuticals Shares Rise After Closing Alkeus Pharmaceuticals Acquisition
2026-09-04 · Tarsus Pharmaceuticals Closes Acquisition of Alkeus Pharmaceuticals
2026-09-04 · Tarsus Pharmaceuticals Completes Acquisition of Alkeus Pharmaceuticals, Expanding Leadership in Eye Care
2026-09-01 · Tarsus to Participate in Upcoming Investor Conferences
2026-08-13 · Tarsus Pharmaceuticals (TARS) Stock Looks Reasonable On Sales While Earnings Stay Weak
2026-08-13 · Tarsus (TARS) Q2 2026 Earnings Call Transcript
2026-08-12 · Oppenheimer Adjusts PT on Tarsus Pharmaceuticals to $100 From $97, Keeps Outperform Rating
Price (daily)
Full chart · RSI · MACD · patterns